Krepp Sarah sold $562K of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 7,864 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.56M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Jul 15, 2026, 12:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the sale for sentiment monitoring, but it is unlikely to change valuation without accompanying fundamental news.

03

What to watch

The disclosure does not state motives; 10b5-1 sales are often scheduled for diversification or liquidity, reducing interpretability versus unscheduled sales.

Relevance 4/10Novelty 3/10Timing: Filed July 14 after July 13 insider sale execution.

Background

The article is an SEC Form 4 insider transaction report for Liquidia Corp, filed the day after the trades.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Krepp Sarah, Chief Human Resource Officer, sold 7,864 shares in open-market trades under a 10b5-1 plan on July 13.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and typically fades unless paired with other news.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and it does not include new company fundamentals, guidance, or regulatory/clinical developments.

Market effects

No clear sector read-through from a single HR officer’s 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted as confidence erosion by some traders, especially if it coincides with other negative signals not mentioned here.

Key entities

  • Liquidia Corp

    Company whose insider transaction is disclosed on Form 4.

  • Krepp Sarah

    Chief Human Resource Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.